Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RIBS V (Restenosis Intra-stent of Bare Metal Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent). A Prospective, Multicenter and Randomized Clinical Trial.

X
Trial Profile

RIBS V (Restenosis Intra-stent of Bare Metal Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent). A Prospective, Multicenter and Randomized Clinical Trial.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 05 May 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Paclitaxel (Primary)
  • Indications Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms RIBS-V
  • Most Recent Events

    • 01 May 2021 Results of pooled analysis from ribs IV and V studies assessing influence of neoatherosclerosis on the prognosis and response to treatment of patients with SR published in the Revista Espanola de Cardiologia
    • 05 Jan 2017 Results (n=249) of pooled analysis of RIBS IV and RIBS V studies assessing the safety and efficacy of DEB in patients with ISR, published in the American Journal of Cardiology
    • 08 Dec 2015 Results (pooled analysis of RIBS IV and RIBS V trials) published in the American Journal of Cardiology (n = 442).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top